Trilegal has advised JB Pharmaceuticals in its acquisition of a portfolio of specific ophthalmology brands from Novartis for INR10.9 billion (USD131 million), comprising trademark licensing and distribution agreements.
JB Pharmaceuticals formalised a INR9.6 billion trademark licence agreement with Novartis Innovative Therapies to acquire a selection of its ophthalmology brands.
Additionally, JB Pharmaceuticals struck a INR1.25 billion promotion and distribution agreement with Novartis Healthcare for these brands within the Indian market for three years from December 2023.
Trilegal partners Clarence Anthony and Harsh Maggon led the team, with the assistance of senior associate Nidhi Singla, and associates Shanika Bhowmick and Vivek Vishwanathan. Additionally, Vadiraja PS contributed as a principal consultant.
